The reduction in ACE2 expression due to SARS-CoV-2 infection may hamper its tumor-suppressive and immune-activating effects in UCEC and KIRP which may worsen the prognosis of COVID-19 in these patients. This evidence concerns the gene ACE2 and COVID-19.